Literature DB >> 33560445

Distinguishing Blau Syndrome from Systemic Sarcoidosis.

Katherine P Kaufman1,2, Mara L Becker3.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide a framework to distinguish Blau syndrome/Early Onset Sarcoidosis and Sarcoidosis clinically. We also discuss relevant differences in genetics, pathogenesis, and management of these diseases. RECENT
FINDINGS: Blau syndrome and Sarcoidosis share the characteristic histologic finding of noncaseating granulomas as well as some similar clinical characteristics; nevertheless, they are distinct entities with important differences between them. Blau syndrome and Early Onset Sarcoidosis are due to one of numerous possible gain-of-function mutations in NOD2, commonly presenting before age 5 with a triad of skin rash, arthritis, and uveitis. However, as more cases are reported, expanded clinical manifestations have been described. In systemic Sarcoidosis, there are numerous susceptibility genes that have been identified, and disease is thought to result from an environmental exposure in a genetically susceptible host. It most often presents with constitutional symptoms and pulmonary involvement and typically affects adolescents and adults. This paper reviews the similarities and differences between Blau syndrome and Sarcoidosis. We also discuss the importance of distinguishing between them, particularly with regard to prognosis and outcomes.

Entities:  

Keywords:  Blau syndrome; NOD2 mutation; Sarcoidosis; Systemic Sarcoidosis

Year:  2021        PMID: 33560445     DOI: 10.1007/s11882-021-00991-3

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  54 in total

Review 1.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

2.  Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16.

Authors:  G Tromp; H Kuivaniemi; S Raphael; L Ala-Kokko; A Christiano; E Considine; R Dhulipala; J Hyland; A Jokinen; S Kivirikko; R Korn; S Madhatheri; S McCarron; L Pulkkinen; H Punnett; K Shimoya; L Spotila; A Tate; C J Williams
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

Review 3.  New concepts in the pathogenesis of sarcoidosis.

Authors:  David Bennett; Elena Bargagli; Rosa Metella Refini; Paola Rottoli
Journal:  Expert Rev Respir Med       Date:  2019-08-23       Impact factor: 3.772

4.  Sarcoidosis in black women in the United States: data from the Black Women's Health Study.

Authors:  Yvette C Cozier; Jeffrey S Berman; Julie R Palmer; Deborah A Boggs; David M Serlin; Lynn Rosenberg
Journal:  Chest       Date:  2010-07-01       Impact factor: 9.410

Review 5.  Epidemiology and clinical characteristics of sarcoidosis: an update from a population-based cohort study from Olmsted County, Minnesota.

Authors:  P Ungprasert; C S Crowson; E L Matteson
Journal:  Reumatismo       Date:  2017-05-22

6.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

7.  CARD15 mutations in Blau syndrome.

Authors:  C Miceli-Richard; S Lesage; M Rybojad; A M Prieur; S Manouvrier-Hanu; R Häfner; M Chamaillard; H Zouali; G Thomas; J P Hugot
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

8.  Familial granulomatous arthritis, iritis, and rash.

Authors:  E B Blau
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

9.  NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.

Authors:  Juan I Aróstegui; Cristina Arnal; Rosa Merino; Consuelo Modesto; María Antonia Carballo; Purificación Moreno; Julia García-Consuegra; Antonio Naranjo; Eduardo Ramos; Pilar de Paz; Josefa Rius; Susana Plaza; Jordi Yagüe
Journal:  Arthritis Rheum       Date:  2007-11

Review 10.  Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis.

Authors:  Patompong Ungprasert; Jay H Ryu; Eric L Matteson
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-08-02
View more
  3 in total

Review 1.  Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.

Authors:  Tomoko Matsuda; Naotomo Kambe; Riko Takimoto-Ito; Yoko Ueki; Satoshi Nakamizo; Megumu K Saito; Syuji Takei; Nobuo Kanazawa
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

Review 2.  Multimodal imaging in pediatric uveitis.

Authors:  Fitz Gerald I Diala; Kayne McCarthy; Judy L Chen; Edmund Tsui
Journal:  Ther Adv Ophthalmol       Date:  2021-12-06

3.  Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome.

Authors:  Shao-Yu Chang; Naotomo Kambe; Wen-Lang Fan; Jing-Long Huang; Wen-I Lee; Chao-Yi Wu
Journal:  Pediatr Rheumatol Online J       Date:  2022-10-03       Impact factor: 3.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.